Phoenix Biotech Acquisition Corp
NASDAQ:CERO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kunshan TopA Intelligent Equipment Co Ltd
SZSE:300836
|
CN |
Phoenix Biotech Acquisition Corp
Stock-Based Compensation
Phoenix Biotech Acquisition Corp
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Phoenix Biotech Acquisition Corp
NASDAQ:CERO
|
Stock-Based Compensation
$929.1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
WP Carey Inc
NYSE:WPC
|
Stock-Based Compensation
$39.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
20%
|
CAGR 10-Years
6%
|
|
|
AltC Acquisition Corp
NYSE:OKLO
|
Stock-Based Compensation
$41.8m
|
CAGR 3-Years
424%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Annaly Capital Management Inc
NYSE:NLY
|
Stock-Based Compensation
$26m
|
CAGR 3-Years
6%
|
CAGR 5-Years
32%
|
CAGR 10-Years
36%
|
|
|
Ares Capital Corp
NASDAQ:ARCC
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SoFi Technologies Inc
NASDAQ:SOFI
|
Stock-Based Compensation
$262.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Phoenix Biotech Acquisition Corp
Glance View
Phoenix Biotech Acquisition Corp. operates as a blank check company. The company is headquartered in Philadelphia, Pennsylvania. The company went IPO on 2021-10-06. The firm is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The firm has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. The company intends to focus its search on the healthcare or healthcare related industries in the United States and Europe. The firm has not commenced any operations nor generated any revenues.
See Also
What is Phoenix Biotech Acquisition Corp's Stock-Based Compensation?
Stock-Based Compensation
929.1k
USD
Based on the financial report for Dec 31, 2024, Phoenix Biotech Acquisition Corp's Stock-Based Compensation amounts to 929.1k USD.
What is Phoenix Biotech Acquisition Corp's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 1Y
859%
Over the last year, the Stock-Based Compensation growth was 859%.
